Cargando…
MxA mRNA decrease preceding NAb detection in IFNβ‐treated MS patients
BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNβ) are at risk of a declining response to treatment because of the production of IFNβ‐neutralizing antibodies (NAbs). The expression of Myxovirus resistance protein A (MxA) mRNA is regarded as a marker of IFNβ bioactivity....
Autores principales: | Libertinova, Jana, Meluzinova, Eva, Matoska, Vaclav, Zajac, Miroslav, Kovarova, Ivana, Havrdova, Eva, Horakova, Dana, Tomek, Ales, Marusic, Petr, Bojar, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346526/ https://www.ncbi.nlm.nih.gov/pubmed/28293479 http://dx.doi.org/10.1002/brb3.644 |
Ejemplares similares
-
Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ
por: Libertinova, Jana, et al.
Publicado: (2017) -
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017) -
The Curious Case of Type I IFN and MxA: Tipping the Immune Balance in AIDS
por: Furuya, Andrea Kinga Marias, et al.
Publicado: (2014) -
Detection of new biallelic polymorphisms in the human MxA gene
por: Duc, Tam Tran Thi, et al.
Publicado: (2012) -
Ribavirin Enhances IFN-α Signalling and MxA Expression: A Novel Immune Modulation Mechanism during Treatment of HCV
por: Stevenson, Nigel J., et al.
Publicado: (2011)